GlassScriptPhysician profile
Stephen Daniel Defronzo
NPI 1922056548
$5,711.98
in general payments reported to CMS, 2019-2025
18 companies · $975 in 2025
The $975 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $148 · 2021: $954 · 2022: $1,050 · 2023: $1,007 · 2024: $777 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,113.61 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $1,561.47 | 2019-2025 | Biktarvy, Sunlenca |
| Janssen Biotech, INC. | $517.47 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $344.62 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Products, LP | $246.98 | 2019-2022 | |
| Theratechnologies INC. | $176.05 | 2023-2024 | Trogarzo, Egrifta Sv, Egrifta |
| Insmed, INC. | $159.28 | 2024-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $145.55 | 2021-2025 | Nuzyra |
| Napo Pharmaceuticals INC | $138.09 | 2023-2025 | Mytesi |
| Genentech USA, INC. | $107.51 | 2019-2022 | |
| Vyera Pharmaceuticals, LLC | $41.37 | 2021-2022 | |
| Allergan, INC. | $32.67 | 2019 | |
| Emd Serono, INC. | $30.33 | 2023-2024 | Serostim |
| Pfizer INC. | $27.70 | 2021-2023 | |
| Nabriva Therapeutics, Plc | $23.45 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.13 | 2025 | Veozah |
| Abbvie INC. | $13.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Defronzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.